Actively Recruiting
Phase 3 Study of 611 Injection for Treating Moderate to Severe COPD in Chinese Adults Aged 40 to 85
Led by Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. · Updated on 2025-11-18
594
Participants Needed
4
Research Sites
8 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the efficacy and safety of the drug 611 in Chinese adults with moderate to severe chronic obstructive pulmonary disease COPD. The study focuses on patients aged 40 to 85 years who have a documented COPD diagnosis and a history of exacerbations. This Phase III clinical trial is sponsored by Sunshine Guojian Pharmaceutical Shanghai Co., Ltd. and aims to assess how 611 affects COPD outcomes compared with a placebo. Participants will be randomly assigned to receive either 611 or a placebo via subcutaneous injection every two weeks during a 52-week treatment period following up to 6 weeks of screening. After treatment, participants will be followed for an additional 8 weeks. The study uses a double-blinded design to compare the effects of 611 on COPD symptoms and exacerbations. During the trial, participants will undergo regular assessments including lung function tests, symptom questionnaires, and monitoring for COPD exacerbations. Researchers will also track adverse events and measure drug levels and immune responses in the blood. The primary outcome is the annualized rate of moderate or severe COPD exacerbations over 52 weeks. The total study duration for each participant is up to 66 weeks, including follow-up.
CONDITIONS
Brief Title
Evaluation of 611 in Chinese Adults Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Research Team
Q
Qinghong Zhou, Master
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here